Curr Diab Rep (2015) 15:43 DOI 10.1007/s11892-015-0617-2
GENETICS (AP MORRIS, SECTION EDITOR)
Genetics of Drug Response in Type 2 Diabetes Ivan Tkáč 1
# Springer Science+Business Media New York 2015
Abstract The introduction of several new drug groups into the treatment of type 2 diabetes in the past few decades leads to an increased requirement for an individualized treatment approach. A personalized treatment is important from the point of view of both efficacy and safety. Recent guidelines are based mainly on entirely phenotypic characteristics such as diabetes duration, presence of macrovascular complications, or risk of hypoglycemia with the use of individual drugs. So far, genetic knowledge is used to guide treatment in the monogenic forms of diabetes. With the accumulating pharmacogenetic evidence in type 2 diabetes, there are reasonable expectations that genetics might help in the adjustment of drug doses to reduce severe side effects, as well as to make better therapeutic choices among the drugs available for the treatment of diabetes. Keywords Pharmacogenetics . Type 2 diabetes . Metformin . Sulfonylurea . Glitazones . Incretins
Introduction Type 2 diabetes mellitus (T2D) affects almost 1 in 10 people in the developed countries, and its incidence is predicted to increase worldwide in the next decades considerably. While a significant proportion of patients with T2D progresses to This article is part of the Topical Collection on Genetics * Ivan Tkáč [email protected] 1
Department of Internal Medicine 4, P. J. Šafárik University, Faculty of Medicine, L. Pasteur University Hospital, Rastislavova 43, 041 90 Košice, Slovakia
require an insulin treatment, the treatment with oral antidiabetic drugs is frequently sufficient to achieve the main therapeutic goal for glycemic control (HbA1c
GENETICS (AP MORRIS, SECTION EDITOR)
Genetics of Drug Response in Type 2 Diabetes Ivan Tkáč 1
# Springer Science+Business Media New York 2015
Abstract The introduction of several new drug groups into the treatment of type 2 diabetes in the past few decades leads to an increased requirement for an individualized treatment approach. A personalized treatment is important from the point of view of both efficacy and safety. Recent guidelines are based mainly on entirely phenotypic characteristics such as diabetes duration, presence of macrovascular complications, or risk of hypoglycemia with the use of individual drugs. So far, genetic knowledge is used to guide treatment in the monogenic forms of diabetes. With the accumulating pharmacogenetic evidence in type 2 diabetes, there are reasonable expectations that genetics might help in the adjustment of drug doses to reduce severe side effects, as well as to make better therapeutic choices among the drugs available for the treatment of diabetes. Keywords Pharmacogenetics . Type 2 diabetes . Metformin . Sulfonylurea . Glitazones . Incretins
Introduction Type 2 diabetes mellitus (T2D) affects almost 1 in 10 people in the developed countries, and its incidence is predicted to increase worldwide in the next decades considerably. While a significant proportion of patients with T2D progresses to This article is part of the Topical Collection on Genetics * Ivan Tkáč [email protected] 1
Department of Internal Medicine 4, P. J. Šafárik University, Faculty of Medicine, L. Pasteur University Hospital, Rastislavova 43, 041 90 Košice, Slovakia
require an insulin treatment, the treatment with oral antidiabetic drugs is frequently sufficient to achieve the main therapeutic goal for glycemic control (HbA1c
